Naver Invests in JNP Medi... Expanding Healthcare Ecosystem

[Financial News] Naver is expanding its healthcare ecosystem and challenging the global market based on AI technology.
Naver announced on the 13th that it held a 'Naver-JNP Medi Comprehensive Business Agreement Ceremony in the Digital Healthcare Field' attended by Naver's Choi In-hyuk Tech Business CEO, JNP Medi's Jung Kwon-ho CEO, and other officials from both companies.
Naver is investing in JNP Medi, which supports the development of new drugs and innovative medical devices based on software and artificial intelligence technology, and plans to cooperate in enhancing Naver's AI technology and JNP Medi's clinical trial platform in the future.
JNP Medi is a leading digital healthcare company in Korea that provides a clinical trial data platform for pharmaceutical, bio, and medical device companies, and supports CRO services, investment support, and license consulting. It offers various functions such as clinical data management, operation, clinical trials, and quality control based on international standards through its self-developed platform, as well as consulting on new drug and medical device technology transfer strategy establishment and contract negotiations.
Naver plans to closely collaborate with JNP Medi to realize the management and technological independence of clinical trial data, a national strategic asset. Additionally, it aims to implement digital clinical trial capabilities necessary for global expansion by combining AI technology and to build a digital transformation infrastructure across the domestic healthcare ecosystem.
Naver's Choi In-hyuk Tech Business CEO said, “Through this collaboration, both companies plan to jointly discover and invest in promising digital healthcare companies at home and abroad, supporting global market entry and mutual growth,” adding, “We will also contribute to product enhancement by integrating Naver's AI technology with JNP Medi's clinical trial platform expertise.”
Meanwhile, Naver has introduced △Smart Survey, which automatically converts patient medical history into medical terms and records it in EMR, and △Patient Summary, which organizes and analyzes past examination results through AI summary technology. In addition, Naver D2SF has been preemptively investing in promising healthcare startups since 2017, and as of August this year, about 18% of the total investment portfolio consists of healthcare startups.
 


yjjoe@fnnews.com Yoonju Jo Reporter